Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 12, 2010 Travis Hoium	Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool November 9, 2004 Charly Travers	Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.
The Motley Fool May 3, 2005 Charly Travers	Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
The Motley Fool December 23, 2011 Brian Orelli	Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins.
The Motley Fool August 27, 2007 Brian Orelli	Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note.
The Motley Fool April 14, 2008 Brian Orelli	Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost.
The Motley Fool November 15, 2011 Brian Orelli	When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells.
The Motley Fool January 20, 2012 Dan Caplinger	Can Geron Recover in 2012? Let's look at this year's prospects for this company.
The Motley Fool May 21, 2007 Mike Havrilla	Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool September 29, 2010 Brian Orelli	Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool September 20, 2005 Rich Smith	ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.
The Motley Fool November 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool August 19, 2010 Brian Orelli	The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology.
The Motley Fool May 15, 2007 Mike Havrilla	Secret Cytori Cytori may be a lesser-known player in the stem-cell therapy field, but it's a stock to watch in the coming year.
The Motley Fool December 8, 2011 Dan Caplinger	Has Geron Become the Perfect Stock? Geron has a modest pipeline of cancer drugs, including imetelstat, which is currently in phase 2 clinical trials.
The Motley Fool December 19, 2008 Brian Orelli	Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation.
The Motley Fool July 26, 2004 Brian Gorman	Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble.
The Motley Fool December 29, 2011 Brian Orelli	What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool November 28, 2007 Brian Orelli	Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool December 1, 2008 Brian Orelli	Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now.
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool August 31, 2007 Brian Orelli	A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending.
AskMen.com Joshua Levine	Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job.
Scientific American January 17, 2007 Charles Q. Choi	A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials.
The Motley Fool October 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.
The Motley Fool June 5, 2007 Brian Lawler	Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note.
The Motley Fool November 20, 2006 Brian Lawler	One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool February 2, 2005 Rich Duprey	Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
The Motley Fool May 2, 2007 Mike Havrilla	Heads Up, Biotech Investors: Chapter 2 Get to know the timing of major catalysts for stocks that may be on your biotech watch list.
Chemistry World April 2006 Karen Harries-Rees	Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool December 22, 2009 Brian Orelli	Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
The Motley Fool October 6, 2011 Brian Orelli	Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important.